{"id":"azd1152-part-a","safety":{"commonSideEffects":["Neutropenia","Thrombocytopenia","Anemia","Fatigue","Nausea"]},"_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Aurora B kinase","explanation":"AZD1152 selectively inhibits Aurora B kinase, which plays a critical role in chromosome segregation and cytokinesis during mitosis. By blocking this enzyme, the drug causes mitotic catastrophe and apoptosis in rapidly dividing cancer cells.","oneSentence":"Inhibits Aurora B kinase, a protein essential for cell division, leading to mitotic disruption and cancer cell death."},"_scrapedAt":"2026-03-28T05:39:13.103Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123698,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"alisertib","brand":null,"company":"Takeda","rationale":"Aurora A kinase inhibitor for hematologic malignancies"},{"name":"danusertib","brand":null,"company":"Nerviano Medical Sciences","rationale":"Pan-Aurora kinase inhibitor for cancer"}],"description":"AZD1152 part A is an investigational small molecule Aurora B kinase inhibitor developed by AstraZeneca for cancer treatment. It was evaluated in early-phase clinical trials for hematologic malignancies and solid tumors, though development appears to have been discontinued.","indications":{"approved":[{"status":"investigational","condition":"Acute myeloid leukemia","patientPopulation":"Adult, relapsed/refractory"},{"status":"investigational","condition":"Advanced solid tumors","patientPopulation":"Adult"}]},"trialDetails":[{"nctId":"NCT03217838","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2017-07-31","conditions":"Acute Myeloid Leukaemia","enrollment":50},{"nctId":"NCT00338182","phase":"PHASE1","title":"AZD1152 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05-23","conditions":"Tumors","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AZD1152 part A","genericName":"AZD1152 part A","companyName":"AstraZeneca","companyId":"astrazeneca","firstApprovalDate":"","aiSummary":"AZD1152 part A is a treatment being studied in a Phase I clinical trial for patients with advanced solid malignancies, including tumors and acute myeloid leukemia. The exact mechanism of AZD1152 part A is unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}